SavedAdd your journal

Journals / International Journal of Health Services Research and Policy / 2026 / Volume: 11 Issue: 2

Moraxella catarrhalis VIRULENCE FACTORS: FROM LOS TO Β -LACTAMASES, VACCINE TARGETS AND RESISTANCE MECHANISMS

Özcan Balıbay(DICLE UNIVERSITY, SCHOOL OF MEDICINE)0000-0002-5771-0092
Nezahat Akpolat(DICLE UNIVERSITY, SCHOOL OF MEDICINE)0000-0002-8653-6046
Erdal Özbek(DICLE UNIVERSITY, SCHOOL OF MEDICINE)0000-0002-8593-224X
Pages
—
Publication Date
2026-06-24
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This article provides fundamental information on virulence factors and their potential targets for vaccine development, as well as treatment strategies focusing on high antibiotic resistance and biofilms.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Moraxella catarrhalis is a Gram-negative diplococcus that causes lower respiratory tract infections in adults and immunocompromised individuals, as well as otitis media in children.
📊
Key Findings & Data:These factors include widely distributed surface lipooligosaccharides (LOS), outer membrane proteins (UspA1, UspA2, UspA2H, OmpCD, Hag/MID, and McaP), type IV pili, biofilm production, iron acquisition systems (CopB, TbpB, LbpB), and β-lactamase production.
💡
Conclusion & Impact:This article provides fundamental information on virulence factors and their potential targets for vaccine development, as well as treatment strategies focusing on high antibiotic resistance and biofilms.
🔬Design:Lab & Field Experiment
📍Scope:Comprehensive Sample
⚙️Variables:Moraxella catarrhalis · Virulence Factors · Molecular mechanisms

Abstract

Moraxella catarrhalis is a Gram-negative diplococcus that causes lower respiratory tract infections in adults and immunocompromised individuals, as well as otitis media in children. Numerous virulence factors associated with M. catarrhalis have been identified. These factors include widely distributed surface lipooligosaccharides (LOS), outer membrane proteins (UspA1, UspA2, UspA2H, OmpCD, Hag/MID, and McaP), type IV pili, biofilm production, iron acquisition systems (CopB, TbpB, LbpB), and β-lactamase production. These structures and systems have been shown to play a critical role in adhesion to epithelial cells, evasion of the immune system, and antibiotic resistance. The prevalence of the LOS A serotype, along with the functional capabilities of the outer membrane proteins UspA1 and PilA to promote adhesion and immune stimulation, make these structures important targets in vaccine development studies. The capacity for biofilm formation and the presence of β-lactamases genes such as bro-1 increase antibiotic resistance, thereby complicating treatment. Recent studies have reported that up to 100% of isolates produce β-lactamases. Iron acquisition systems play a vital role in binding to target cells, protecting against environmental stressors, and bacterial survival. This article provides fundamental information on virulence factors and their potential targets for vaccine development, as well as treatment strategies focusing on high antibiotic resistance and biofilms.

🔖

Cite This Article

Balıbay, Ö., Akpolat, N., Özbek, E. (2026). Moraxella catarrhalis VIRULENCE FACTORS: FROM LOS TO Β -LACTAMASES, VACCINE TARGETS AND RESISTANCE MECHANISMS. International Journal of Health Services Research and Policy, Volume: 11 Issue: 2. https://doi.org/10.33457/ijhsrp.1882430

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (55)

  1. K. Yao and D. Liu, “Moraxella catarrhalis,” in Molecular Medical Microbiology, Y. W. Tang, M. Sussman, D. Liu, I. Poxton, and J. Schwartzman, Eds. Amsterdam, The Netherlands: Academic Press, 2024, pp. 1503–1517.
  2. A. L. Leber, Clinical Microbiology Procedures Handbook. Washington, DC, USA: ASM Press/Wiley, 2020.
  3. A. S. Jaber, “Moraxella catarrhalis: The virulence factor and pathogenesis strategy,” J. Infect. Public Health, vol. 14, no. 5, pp. 625–632, 2021, doi: 10.1016/j.jiph.2021.02.012.
  4. D. E. Morris, “The epidemiology of Moraxella catarrhalis,” Ph.D. dissertation, Univ. Southampton, Southampton, U.K., 2022.
  5. H. Smith, “The state and future of studies on bacterial pathogenicity,” J. Gen. Microbiol., vol. 134, no. 1, pp. 1–10, 1988, doi: 10.1099/00221287-134-1-1.
  6. M. L. P. Vidakovics and K. Riesbeck, “Virulence mechanisms of Moraxella in the pathogenesis of infection,” Curr. Opin. Infect. Dis., vol. 22, no. 3, pp. 279–285, 2009, doi: 10.1097/QCO.0b013e32832b5d5d.
  7. A. S. Alexandrova, V. S. Boyanov, K. Y. Mihova, and R. T. Gergova, “Phylogenetic lineages and diseases associated with Moraxella catarrhalis isolates recovered from Bulgarian patients,” Int. J. Mol. Sci., vol. 25, no. 18, Art. no. 9769, 2024, doi: 10.3390/ijms25189769.
  8. D. E. Morris, K. L. Osman, D. W. Cleary, and S. C. Clarke, “The characterization of Moraxella catarrhalis carried in the general population,” Microb. Genom., vol. 8, no. 5, Art. no. 000820, 2022, doi: 10.1099/mgen.0.000820.
  9. S. J. Verhaegh, A. Streefland, J. K. Dewnarain, D. J. Farrell, A. van Belkum, and J. P. Hays, “Age-related genotypic and phenotypic differences in Moraxella catarrhalis isolates from children and adults presenting with respiratory disease,” Microbiology, vol. 154, no. 4, pp. 1178–1184, 2008, doi: 10.1099/mic.0.2007/012062-0.
  10. M. Vaneechoutte, G. Verschraegen, G. Claeys, and A. M. Van Den Abeele, “Serological typing of Branhamella catarrhalis strains on the basis of lipopolysaccharide antigens,” J. Clin. Microbiol., vol. 28, no. 2, pp. 182–187, 1990, doi: 10.1128/jcm.28.2.182-187.1990.
  11. N. Zhao, H. Ren, J. Deng, Y. Du, Q. Li, and P. Zhou, “Genotypic and phenotypic characteristics of Moraxella catarrhalis from patients and healthy asymptomatic participants among preschool children,” Pathogens, vol. 11, no. 9, Art. no. 984, 2022, doi: 10.3390/pathogens11090984.
  12. I. G. Mitov, R. T. Gergova, and V. V. Ouzounova-Raykova, “Distribution of genes encoding virulence factors ompB2, ompCD, ompE, β-lactamase and serotype in pathogenic and colonizing strains of Moraxella catarrhalis,” Arch. Med. Res., vol. 41, no. 7, pp. 530–535, 2010, doi: 10.1016/j.arcmed.2010.10.001.
  13. K. J. Edwards, J. M. Schwingel, A. K. Datta, and A. A. Campagnari, “Multiplex PCR assay that identifies the major lipooligosaccharide serotype expressed by Moraxella catarrhalis clinical isolates,” J. Clin. Microbiol., vol. 43, no. 12, pp. 6139–6143, 2005, doi: 10.1128/JCM.43.12.6139-6143.2005.
  14. D. J. Hill, A. M. Edwards, H. A. Rowe, and M. Virji, “Carcinoembryonic antigen-related cell adhesion molecule-binding recombinant polypeptide confers protection against infection by respiratory and urogenital pathogens,” Mol. Microbiol., vol. 55, no. 5, pp. 1515–1527, 2005, doi: 10.1111/j.1365-2958.2005.04482.x.
  15. E. R. Lafontaine, L. D. Cope, C. Aebi, J. L. Latimer, G. H. McCracken, Jr., and E. J. Hansen, “The UspA1 protein and a second type of UspA2 protein mediate adherence of Moraxella catarrhalis to human epithelial cells in vitro,” J. Bacteriol., vol. 182, no. 5, pp. 1364–1373, 2000, doi: 10.1128/JB.182.5.1364-1373.2000.
  16. L. V. Blakeway, A. Tan, I. R. Peak, and K. L. Seib, “Virulence determinants of Moraxella catarrhalis: Distribution and considerations for vaccine development,” Microbiology, vol. 163, no. 10, pp. 1371–1384, 2017, doi: 10.1099/mic.0.000533.
  17. E. Dissanayake, R. A. Brockman-Schneider, R. M. Stubbendieck, B. A. Helling, Z. Zhang, Y. A. Bochkov, et al., “Rhinovirus enhances Moraxella catarrhalis adherence to respiratory epithelium,” Front. Cell. Infect. Microbiol., vol. 12, Art. no. 1060748, 2023, doi: 10.3389/fcimb.2022.1060748.
  18. D. Donnarumma, F. Giusti, C. Ysebaert, P. Hermand, N. Devos, I. Ferlenghi, et al., “FHUSPA2/10 is a bactericidal monoclonal antibody targeting multiple repeated sequences of Moraxella catarrhalis UspA2,” Vaccine, vol. 40, no. 45, pp. 6520–6527, 2022, doi: 10.1016/j.vaccine.2022.09.034.
  19. V. Spaniol, N. Heiniger, R. Troller, and C. Aebi, “Outer membrane protein UspA1 and lipooligosaccharide are involved in invasion of human epithelial cells by Moraxella catarrhalis,” Microbes Infect., vol. 10, no. 1, pp. 3–11, 2008, doi: 10.1016/j.micinf.2007.09.007.
  20. J. C. McMichael, “Vaccines for Moraxella catarrhalis,” Vaccine, vol. 19, Suppl. 1, pp. S101–S107, 2000, doi: 10.1016/S0264-410X(00)00287-5.
  21. T. T. Tan, T. Nordström, A. Forsgren, and K. Riesbeck, “The respiratory pathogen Moraxella catarrhalis adheres to epithelial cells by interacting with fibronectin through ubiquitous surface proteins A1 and A2,” J. Infect. Dis., vol. 192, no. 6, pp. 1029–1038, 2005, doi: 10.1086/432731.
  22. S. J. C. Verhaegh, “Epidemiology and pathogenesis of Moraxella catarrhalis colonization and infection,” Ph.D. dissertation, Erasmus Univ., Rotterdam, The Netherlands, 2011.
  23. M. Nawa, J. Mwansa, J. Mwaba, P. Kaonga, A. N. Mukubesa, M. Simuyandi, et al., “Microbiologic and virulence characteristics of Moraxella catarrhalis isolates from Zambian children presenting with acute pneumonia,” Pediatr. Pulmonol., vol. 57, no. 12, pp. 3084–3093, 2022, doi: 10.1002/ppul.26088.
  24. D. Linke, T. Riess, I. B. Autenrieth, A. Lupas, and V. A. Kempf, “Trimeric autotransporter adhesins: Variable structure, common function,” Trends Microbiol., vol. 14, no. 6, pp. 264–270, 2006, doi: 10.1016/j.tim.2006.04.005.
  25. Y. L. Liu, R. Ding, X. M. Jia, J. J. Huang, S. Yu, H. T. Chan, et al., “Correlation of Moraxella catarrhalis macrolide susceptibility with the ability to adhere and invade human respiratory epithelial cells,” Emerg. Microbes Infect., vol. 11, no. 1, pp. 2055–2068, 2022, doi: 10.1080/22221751.2022.2108341.
  26. M. M. Pearson, “Biofilm formation by Moraxella catarrhalis,” Ph.D. dissertation, Univ. Texas, Dallas, TX, USA, 2004.
  27. T. F. Murphy, A. L. Brauer, M. M. Pettigrew, E. R. LaFontaine, and H. Tettelin, “Persistence of Moraxella catarrhalis in chronic obstructive pulmonary disease and regulation of the Hag/MID adhesin,” J. Infect. Dis., vol. 219, no. 9, pp. 1448–1455, 2019, doi: 10.1093/infdis/jiy694.
  28. A. Möllenkvist, T. Nordström, C. Halldén, J. J. Christensen, and A. Forsgren, “The Moraxella catarrhalis immunoglobulin D-binding protein MID has conserved sequences and is regulated by phase variation,” J. Bacteriol., vol. 185, no. 7, pp. 2285–2295, 2003, doi: 10.1128/JB.185.7.2285-2295.2003.
  29. M. M. Holm, S. L. Vanlerberg, I. M. Foley, D. D. Sledjeski, and E. R. Lafontaine, “The Moraxella catarrhalis porin-like outer membrane protein CD is an adhesin for human lung cells,” Infect. Immun., vol. 72, no. 4, pp. 1906–1913, 2004, doi: 10.1128/IAI.72.4.1906-1913.2004.
  30. T. F. Murphy, C. Kirkham, D. F. Liu, and S. Sethi, “Human immune response to outer membrane protein CD of Moraxella catarrhalis in adults with chronic obstructive pulmonary disease,” Infect. Immun., vol. 71, no. 3, pp. 1288–1294, 2003, doi: 10.1128/IAI.71.3.1288-1294.2003.
  31. S. L. Lipski, C. Akimana, J. M. Timpe, R. M. Wooten, and E. R. Lafontaine, “The Moraxella catarrhalis autotransporter McaP is a conserved surface protein that mediates adherence to human epithelial cells through its N-terminal passenger domain,” Infect. Immun., vol. 75, no. 1, pp. 314–324, 2007, doi: 10.1128/IAI.01195-06.
  32. K. L. Bair and A. A. Campagnari, “Moraxella catarrhalis promotes stable polymicrobial biofilms with the major otopathogens,” Front. Microbiol., vol. 10, Art. no. 3006, 2020, doi: 10.3389/fmicb.2019.03006.
  33. M. H. Ghaffoori Kanaan, H. R. Al-abodi, S. S. Abdullah, M. Memariani, M. Kohansal, and A. Ghasemian, “Biofilm formation and drug resistance determinants of Moraxella catarrhalis, Moraxella osloensis and Moraxella lacunata from clinical samples in Iraq,” Health Biotechnol. Biopharma, vol. 7, no. 4, pp. 81–97, 2024, doi: 10.22034/HBB.2024.05.
  34. M. M. Pearson, C. A. Laurence, S. E. Guinn, and E. J. Hansen, “Biofilm formation by Moraxella catarrhalis in vitro: Roles of the UspA1 adhesin and the Hag hemagglutinin,” Infect. Immun., vol. 74, no. 3, pp. 1588–1596, 2006, doi: 10.1128/IAI.74.3.1588-1596.2006.
  35. N. R. Luke-Marshall, S. L. Sauberan, and A. A. Campagnari, “Comparative analyses of the Moraxella catarrhalis type IV pilus structural subunit PilA,” Gene, vol. 477, no. 1–2, pp. 19–23, 2011, doi: 10.1016/j.gene.2011.01.009.
  36. V. Karuppiah, R. F. Collins, A. Thistlethwaite, et al., “Structure and assembly of an inner membrane platform for initiation of type IV pilus biogenesis,” Proc. Natl. Acad. Sci. USA, vol. 110, no. 48, pp. E4638–E4647, 2013, doi: 10.1073/pnas.1313955110.
  37. T. L. Leighton, M. C. Mok, M. S. Junop, et al., “Conserved, unstructured regions in Pseudomonas aeruginosa PilO are important for type IVa pilus function,” Sci. Rep., vol. 8, Art. no. 17819, 2018, doi: 10.1038/s41598-018-36009-0.
  38. E. M. Mokrzan, L. A. Novotny, K. L. Brockman, and L. O. Bakaletz, “Antibodies against the majority subunit (PilA) of the type IV pilus disperse Moraxella catarrhalis from a dual-species biofilm,” mBio, vol. 9, no. 6, Art. no. e02423-18, 2018, doi: 10.1128/mBio.02423-18.
  39. S. P. de Vries, H. J. Bootsma, J. P. Hays, and P. W. Hermans, “Molecular aspects of Moraxella catarrhalis pathogenesis,” Microbiol. Mol. Biol. Rev., vol. 73, no. 3, pp. 389–406, 2009, doi: 10.1128/MMBR.00010-09.
  40. S. Chochua, V. D’Acremont, C. Hanke, et al., “Increased nasopharyngeal density and concurrent carriage of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are associated with pneumonia in febrile children,” PLoS One, vol. 11, no. 12, Art. no. e0167725, 2016, doi: 10.1371/journal.pone.0167725.
  41. R. A. Bonnah, H. Wong, S. M. Loosmore, et al., “Characterization of Moraxella (Branhamella) catarrhalis lbpB, lbpA and lactoferrin receptor isogenic mutants,” Infect. Immun., vol. 67, no. 3, pp. 1517–1520, 1999, doi: 10.1128/iai.67.3.1517-1520.1999.
  42. N. K. H. Ostan, R. H. Yu, D. Ng, et al., “Lactoferrin binding protein B: A bi-functional bacterial receptor protein,” PLoS Pathog., vol. 13, no. 3, Art. no. e1006244, 2017, doi: 10.1371/journal.ppat.1006244.
  43. C. Chan, D. Ng, and A. B. Schryvers, “The role of the Moraxella catarrhalis CopB protein in facilitating iron acquisition from human transferrin and lactoferrin,” Front. Microbiol., vol. 12, Art. no. 714815, 2021, doi: 10.3389/fmicb.2021.714815.
  44. D. Augustyniak, R. Seredyński, S. McClean, et al., “Virulence factors of Moraxella catarrhalis outer membrane vesicles are major targets for cross-reactive antibodies and have adapted during evolution,” Sci. Rep., vol. 8, Art. no. 4955, 2018, doi: 10.1038/s41598-018-23252-1.
  45. V. Spaniol, R. Troller, A. Schaller, et al., “Physiologic cold shock of Moraxella catarrhalis affects the expression of genes involved in iron acquisition, serum resistance and immune evasion,” BMC Microbiol., vol. 11, Art. no. 1, 2011, doi: 10.1186/1471-2180-11-1.
  46. N. R. Luke, A. J. Howlett, J. Shao, et al., “Expression of type IV pili by Moraxella catarrhalis is essential for natural competence and is affected by iron limitation,” Infect. Immun., vol. 72, no. 11, pp. 6262–6270, 2004, doi: 10.1128/IAI.72.11.6262-6270.2004.
  47. B. E. Malmvall, J. E. Brorsson, and J. Johnsson, “In vitro sensitivity to penicillin V and β-lactamase production of Branhamella catarrhalis,” Scand. J. Infect. Dis., vol. 9, no. 1, pp. 33–36, 1977, doi: 10.3109/00365547709152010.
  48. A. Percival, J. E. Corkill, J. Rowlands, et al., “Pathogenicity of and β-lactamase production by Branhamella (Neisseria) catarrhalis,” Lancet, vol. 310, no. 8049, p. 1175, 1977, doi: 10.1016/S0140-6736(77)91858-5.
  49. S. Maraki and I. S. Papadakis, “Antimicrobial resistance trends among community-acquired respiratory tract pathogens in Greece, 2009–2012,” Sci. World J., vol. 2014, Art. no. 941564, 2014, doi: 10.1155/2014/941564.
  50. Y. Zhang, F. Zhang, H. Wang, et al., “Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated from community-acquired respiratory tract infections in China: Results from the CARTIPS antimicrobial surveillance program,” J. Glob. Antimicrob. Resist., vol. 5, pp. 36–41, 2016, doi: 10.1016/j.jgar.2015.11.006.
  51. S. Raveendran, R. Rajan, K. C. Shivanandappa, et al., “Moraxella catarrhalis: A cause of concern with emerging resistance and presence of BRO β-lactamase gene-report from a tertiary care hospital in South India,” Int. J. Microbiol., vol. 2020, Art. no. 7316257, 2020, doi: 10.1155/2020/7316257.
  52. R. J. Wallace, Jr., V. A. Steingrube, D. R. Nash, et al., “BRO beta-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactamase transfer by conjugation,” Antimicrob. Agents Chemother., vol. 33, no. 11, pp. 1845–1854, 1989, doi: 10.1128/AAC.33.11.1845.
  53. H. J. Bootsma, H. van Dijk, J. Verhoef, et al., “Genesis of BRO beta-lactamase-producing Moraxella catarrhalis: Evidence for transformation-mediated horizontal transfer,” Mol. Microbiol., vol. 36, no. 1, pp. 93–104, 2000, doi: 10.1046/j.1365-2958.2000.01828.x.
  54. F. J. Schmitz, A. Beeck, M. Perdikouli, et al., “Production of BRO beta-lactamases and resistance to complement in European Moraxella catarrhalis isolates,” J. Clin. Microbiol., vol. 40, no. 9, pp. 3164–3170, 2002, doi: 10.1128/JCM.40.9.3164-3170.2002.
  55. Y. Xiang, J. Shi, L. Han, et al., “Pathogenicity and Bro gene typing of pediatric lower respiratory tract infections with Moraxella catarrhalis in Southwest Shandong, China,” Sci. Rep., vol. 15, Art. no. 15070, 2025, doi: 10.1038/s41598-025-99873-1.